KR870001832A - 비경구용 페니토인 조성물 - Google Patents

비경구용 페니토인 조성물 Download PDF

Info

Publication number
KR870001832A
KR870001832A KR1019860006690A KR860006690A KR870001832A KR 870001832 A KR870001832 A KR 870001832A KR 1019860006690 A KR1019860006690 A KR 1019860006690A KR 860006690 A KR860006690 A KR 860006690A KR 870001832 A KR870001832 A KR 870001832A
Authority
KR
South Korea
Prior art keywords
intravenous fluid
formulation
ethanol
propylene glycol
group
Prior art date
Application number
KR1019860006690A
Other languages
English (en)
Inventor
카오 슈이-흐시
아이. 카이 알렌
제이. 샘프손 카라
Original Assignee
스테펜 레이니스
워너-람버트 캄퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테펜 레이니스, 워너-람버트 캄퍼니 filed Critical 스테펜 레이니스
Publication of KR870001832A publication Critical patent/KR870001832A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음.

Description

비경구용 페니토인 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 약 1∼10wt.% 페니토인소듐 및 약 3∼17wt.% 폴리비닐피롤리돈을 포함한 주사가능한 조성물.
  2. 제1항의 조성물 및 최소한 하나의 정맥내 유체로 구성원 수성 제제.
  3. 제2항에 있어서, 정맥내 유체가 식염수 용액인 제제.
  4. 제2항에 있어서, 정맥내 유체가 포도당 용액인 제제.
  5. 프로필렌 글리콜 및 에탄올로 구성된 그룹으로부터 선택된 최소한 하나의 알콜성 용매로 더 구성된 제1항의 조성물.
  6. 프로필렌 클리콜 및 에탄올로 구성된 그룹으로부터 선택된 최소한 하나의 알콜성 용매로 더 구성된 제3항의 제제.
  7. 프로필렌 클리콜 및 에탄올로 구성된 그룹으로부터 선택된 최소한 하나의 알콜성 용매로 더 구성된 제4항의 제제.
  8. 토니토인소듐을 투약하기 위해 수성 용액에 페니토인소듐 및 폴리비닐피롤리돈을 용해시키는: 단계로, 구성된 수성제제의 제조방법.
  9. 페니토인스듐 대 PVP의 비가 약 1:0.5∼1:3.5인 물질을 환자에게 투약하는 것을 포함하는 항경련제의 투약 방법.
  10. 제9항에 있어서, 프로필렌 글리콜 및 에탄올로 구성된 그룹으로부터 선택된 것안 최소한 하나익 알콜성 용매를 부가적으로 포함하는 물질인 방법.
  11. 제10항에 있어서, 최소한 하나의 정맥내 유체를 부가적으로 포함하는 물질인 방법.
  12. 제11항에 있어서, 정맥내 유체가 식염수 용액인 방법.
  13. 제11항에 있어서, 정맥내 유체가 포도당 용액인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860006690A 1985-08-21 1986-08-14 비경구용 페니토인 조성물 KR870001832A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US767,997 1985-08-21
US06/767,997 US4696814A (en) 1985-08-21 1985-08-21 Parenteral phenytoin compositions

Publications (1)

Publication Number Publication Date
KR870001832A true KR870001832A (ko) 1987-03-28

Family

ID=25081202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860006690A KR870001832A (ko) 1985-08-21 1986-08-14 비경구용 페니토인 조성물

Country Status (9)

Country Link
US (1) US4696814A (ko)
EP (1) EP0212853A3 (ko)
JP (1) JPS6245524A (ko)
KR (1) KR870001832A (ko)
AU (1) AU581319B2 (ko)
DK (1) DK396986A (ko)
NZ (1) NZ217297A (ko)
PH (1) PH22146A (ko)
ZA (1) ZA864300B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
AU6001790A (en) * 1989-08-02 1991-02-07 Warner-Lambert Company Formulations of phenytoin sodium for intravenous administration
ES2399480T3 (es) * 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
WO2004058152A2 (en) * 2002-12-16 2004-07-15 Ranbaxy Pharmaceuticals Inc. An extended release pharmaceutical composition of phenytoin sodium
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
EP2286800A1 (en) * 2005-04-11 2011-02-23 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US8377979B2 (en) * 2005-12-05 2013-02-19 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
IL52533A (en) * 1977-07-15 1980-01-31 Abic Ltd Injectable chloramphenicol composition
DE3006635A1 (de) * 1980-02-22 1981-08-27 Basf Ag, 6700 Ludwigshafen Verwendung von mikronisiertem vernetztem, unloeslichem polyvinylpyrrolidon zur stabilisierung von suspensionen

Also Published As

Publication number Publication date
AU581319B2 (en) 1989-02-16
DK396986A (da) 1987-02-22
US4696814A (en) 1987-09-29
ZA864300B (en) 1987-02-25
PH22146A (en) 1988-06-01
EP0212853A3 (en) 1987-07-29
DK396986D0 (da) 1986-08-20
AU5847086A (en) 1987-03-12
JPS6245524A (ja) 1987-02-27
EP0212853A2 (en) 1987-03-04
NZ217297A (en) 1988-11-29

Similar Documents

Publication Publication Date Title
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
IT1279383B1 (it) Composizione farmaceutica stabilizzata contenente un agente antineoplastico degradabile, relativo solvente stabilizzante avente
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR890700036A (ko) 비내 투여용 제제 및 그 제조방법
NO166687C (no) Fremgangsmaate for fremstilling av en stabil, vandig, injiserbar opploesning av piroxicam.
KR910009240A (ko) 약제학적 또는 치료학적 활성제의 수송 시스템
KR830002327A (ko) 약학적 제제
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
KR930001896A (ko) 디클로페낙 나트륨 경고제
KR870001832A (ko) 비경구용 페니토인 조성물
KR880001283A (ko) 제약 조성물
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
EA199600024A2 (ru) Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для ее получения
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR920021133A (ko) 경고제(硬膏劑)
KR900002774A (ko) 주사제
KR910015286A (ko) 알킬 사카라이드(saccharides)를 함유하는 제약조성물 및 약물투과를 향상시키기 위한 알킬 사카라이드의 용도
KR920703112A (ko) 의약품 조성물
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
KR910004186A (ko) 제약학적 배합물
KR910700263A (ko) 시클로리노펩티드를 포함하는 의약
KR880000094A (ko) 위염치료제
KR920009395A (ko) 경질 캡슐제제
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL